Prediction of healing in Category I pressure ulcers by skin blotting with plasminogen activator inhibitor 1, interleukin-1α, vascular endothelial growth factor C, and heat shock protein 90α: A pilot study.


Journal

Journal of tissue viability
ISSN: 0965-206X
Titre abrégé: J Tissue Viability
Pays: England
ID NLM: 9306822

Informations de publication

Date de publication:
May 2019
Historique:
received: 18 04 2018
revised: 16 01 2019
accepted: 07 02 2019
pubmed: 26 2 2019
medline: 17 9 2019
entrez: 26 2 2019
Statut: ppublish

Résumé

The prevention of progression of Category I pressure ulcers (PUs) to Category II or higher is important, as Category II or higher PUs are open wounds and have a higher infection risk. Prognosis prediction of Category I PUs is necessary to provide successful intensive care for PUs with impaired healing. We focused on skin blotting using plasminogen activator inhibitor 1 (PAI1), interleukin-1α (IL-1α), vascular endothelial growth factor C (VEGF-C), and heat shock protein 90α (HSP90α). This pilot study was conducted at long-term-care and general hospitals to examine the applicability of DESIGN-R and thermography; the feasibility of skin blotting technique; the biomarker candidates, PAI1, IL-1α, VEGF-C, and HSP90α; and sample size for prognosis prediction for Category I PUs. Patients aged >65 years underwent skin blotting, scoring for DESIGN-R, and took thermography images of their Category I PU site. Albumin signals were not detected in one out of three participants. PAI1, IL-1α, VEGF-C, and HSP90α were detected in 19 participants, among whom 11 participants could be followed up after one week. There was no difference in DESIGN-R score and skin surface temperature between normal and impaired healing groups, and the sample size was calculated as 16. In conclusion, the feasibility of skin blotting was confirmed. PAI1, IL-1α, VEGF-C, and HSP90α could be biomarker candidates for prognosis prediction for Category I PU and the combination of VEGF-C and HSP90α could be associated with the prognosis of Category I PU. We need to investigate 842 patients in a future study.

Identifiants

pubmed: 30799135
pii: S0965-206X(18)30051-2
doi: 10.1016/j.jtv.2019.02.002
pii:
doi:

Substances chimiques

Biomarkers 0
Interleukin-1alpha 0
Plasminogen Activator Inhibitor 1 0
VEGFC protein, human 0
Vascular Endothelial Growth Factor C 0

Types de publication

Journal Article

Langues

eng

Pagination

87-93

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Ayano Nakai (A)

Department of Gerontological Nursing/Wound Care Management, Graduate School of Medicine, The University of Tokyo, Japan. Electronic address: a-nakai@umin.ac.jp.

Takeo Minematsu (T)

Department of Skincare Science, Graduate School of Medicine, The University of Tokyo, Japan; Division of Care Innovation, Global Nursing Research Center, Graduate School of Medicine, The University of Tokyo, Japan. Electronic address: tminematsu-tky@umin.ac.jp.

Nao Tamai (N)

Department of Skincare Science, Graduate School of Medicine, The University of Tokyo, Japan. Electronic address: ntamai-tky@umin.ac.jp.

Junko Sugama (J)

Advanced Health Care Science Research Unit, Innovative Integrated Bio-Research Core, Institute for Frontier Science Initiative, Kanazawa University, Japan. Electronic address: junkosgm@mhs.mp.kanazawa-u.ac.jp.

Tamae Urai (T)

Advanced Health Care Science Research Unit, Innovative Integrated Bio-Research Core, Institute for Frontier Science Initiative, Kanazawa University, Japan. Electronic address: t-urai@umin.ac.jp.

Hiromi Sanada (H)

Department of Gerontological Nursing/Wound Care Management, Graduate School of Medicine, The University of Tokyo, Japan; Division of Care Innovation, Global Nursing Research Center, Graduate School of Medicine, The University of Tokyo, Japan. Electronic address: hsanada-tky@umin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH